Dr Anand Shivnani and colleagues from examined the impact of neoadjuvant chemoradiation for rectal cancer on surgical outcomes.
The team of doctors determined prognostic factors predicting improved survival.
The team evaluated a retrospective cohort of 56 male and 44 female patients.
After preoperative chemoradiation, the team reported that 73% of patients had sphincter-preserving surgery.
|The 5-year overall survival rate was 81%|
|American Journal of Surgery|
The doctors found that the 5-year disease-free and overall survival rates were 77% and 81%, respectively.
The team observed that 25% of patients showed a complete pathologic response.
T-level downstaging and pathologic T stage did not correlate with recurrence or survival rates.
The doctors found that pathologic nodal stage was associated with a significant difference in recurrence rates, and and disease-free survival.
Dr Shivnani's team concluded, “Neoadjuvant chemoradiation resulted in a high rate of sphincter preservation.”
“Complete pathologic responses after surgery were frequent and although pathologic T stage after surgery did not affect recurrence rates.”
“Pathologic nodal response was associated with improved recurrence and survival rates.”